DE602004010314D1 - Behandlung von neurodegenerativen erkrankungen durch verwendung von degs-inhibitoren - Google Patents
Behandlung von neurodegenerativen erkrankungen durch verwendung von degs-inhibitorenInfo
- Publication number
- DE602004010314D1 DE602004010314D1 DE602004010314T DE602004010314T DE602004010314D1 DE 602004010314 D1 DE602004010314 D1 DE 602004010314D1 DE 602004010314 T DE602004010314 T DE 602004010314T DE 602004010314 T DE602004010314 T DE 602004010314T DE 602004010314 D1 DE602004010314 D1 DE 602004010314D1
- Authority
- DE
- Germany
- Prior art keywords
- inhibitors
- treatment
- neurodeegenerative
- degs
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0083—Miscellaneous (1.14.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/19—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water (1.14.19)
- C12Y114/19001—Stearoyl-CoA 9-desaturase (1.14.19.1), i.e. DELTA9-desaturase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96472—Aspartic endopeptidases (3.4.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04018874 | 2004-08-09 | ||
EP04018874 | 2004-08-09 | ||
WOPCT/EP2004/009 | 2004-09-02 | ||
PCT/EP2004/009771 WO2005023833A2 (en) | 2003-09-05 | 2004-09-02 | Treatment of neurodegenerative diseases |
PCT/EP2004/013341 WO2006015622A1 (en) | 2004-08-09 | 2004-11-24 | Treatment of neurodegenerative diseases by the use of degs inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
DE602004010314D1 true DE602004010314D1 (de) | 2008-01-03 |
DE602004010314T2 DE602004010314T2 (de) | 2009-03-05 |
Family
ID=38873800
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004013202T Active DE602004013202T2 (de) | 2004-08-09 | 2004-11-24 | Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren |
DE602004010314T Active DE602004010314T2 (de) | 2004-08-09 | 2004-11-24 | Behandlung von neurodegenerativen erkrankungen durch verwendung von degs-inhibitoren |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004013202T Active DE602004013202T2 (de) | 2004-08-09 | 2004-11-24 | Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren |
Country Status (10)
Country | Link |
---|---|
US (2) | US20070298029A1 (de) |
EP (2) | EP1778837B1 (de) |
JP (2) | JP2008509171A (de) |
AT (1) | ATE392471T1 (de) |
CA (2) | CA2575300A1 (de) |
DE (2) | DE602004013202T2 (de) |
DK (2) | DK1778837T3 (de) |
ES (2) | ES2295949T3 (de) |
PT (1) | PT1778837E (de) |
WO (2) | WO2006015621A1 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
CA2587083A1 (en) | 2004-11-17 | 2006-05-26 | Merck & Co., Inc. | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2006057983A1 (en) * | 2004-11-23 | 2006-06-01 | Merck & Co., Inc. | Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of alzheimer's disease |
PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
CN117903302A (zh) | 2005-11-30 | 2024-04-19 | Abbvie 公司 | 抗-Aβ球聚体抗体,其相关产品,生产所述抗体的方法,所述抗体的应用以及使用方法 |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2486928A1 (de) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Verfahren zur Behandlung von Amyloidosen |
CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
CA2808187A1 (en) | 2010-08-14 | 2012-02-23 | Abbvie Inc. | Amyloid-beta binding proteins |
US9233102B2 (en) | 2012-03-07 | 2016-01-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
EP3529245A4 (de) | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | Verbindungen und verwendungen davon |
IL304017A (en) | 2017-01-06 | 2023-08-01 | Yumanity Therapeutics Inc | Methods for treating neurological disorders |
CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5198346A (en) * | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
US5096815A (en) * | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5498538A (en) * | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DK0546073T3 (da) * | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5582981A (en) * | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
US20020025508A1 (en) * | 2000-01-06 | 2002-02-28 | Katja Fechteler | Process for finding a protease inhibitor |
US20040248243A1 (en) * | 2000-01-21 | 2004-12-09 | Henry Yue | Lipid metabolism enzymes |
AU2001237412A1 (en) * | 2000-02-25 | 2001-09-03 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Presenilin deficient multipotent cell lines and screening methods for intramembrane regulated proteolytic activities using these lines |
US6686185B1 (en) * | 2000-03-07 | 2004-02-03 | Millennium Pharmaceuticals, Inc. | 25934, a novel fatty acid desaturase and uses therefor |
CA2301158A1 (en) * | 2000-03-24 | 2001-09-24 | Stephen J. Allen | Screening methods for compounds useful for modulating lipid metabolism in disease |
US20030198953A1 (en) * | 2000-03-30 | 2003-10-23 | Spytek Kimberly A. | Novel proteins and nucleic acids encoding same |
US20020115606A1 (en) * | 2000-10-17 | 2002-08-22 | Myriad Genetics, Inc. | Protein-protein interactions in neurodegenerative diseases |
ES2170030B1 (es) * | 2000-12-19 | 2003-11-16 | Consejo Superior Investigacion | Inhibidores de la dihidroceramida desaturasa. |
US7276593B2 (en) * | 2000-12-29 | 2007-10-02 | Curagen Corporation | Proteins and nucleic acids encoding same |
-
2004
- 2004-11-24 DK DK04822235T patent/DK1778837T3/da active
- 2004-11-24 DK DK04798068T patent/DK1786442T3/da active
- 2004-11-24 US US11/659,680 patent/US20070298029A1/en not_active Abandoned
- 2004-11-24 AT AT04822235T patent/ATE392471T1/de not_active IP Right Cessation
- 2004-11-24 ES ES04798068T patent/ES2295949T3/es active Active
- 2004-11-24 JP JP2007525181A patent/JP2008509171A/ja not_active Withdrawn
- 2004-11-24 EP EP04822235A patent/EP1778837B1/de not_active Not-in-force
- 2004-11-24 WO PCT/EP2004/013340 patent/WO2006015621A1/en active Application Filing
- 2004-11-24 DE DE602004013202T patent/DE602004013202T2/de active Active
- 2004-11-24 US US11/659,245 patent/US20090098105A1/en not_active Abandoned
- 2004-11-24 WO PCT/EP2004/013341 patent/WO2006015622A1/en active IP Right Grant
- 2004-11-24 DE DE602004010314T patent/DE602004010314T2/de active Active
- 2004-11-24 ES ES04822235T patent/ES2304642T3/es active Active
- 2004-11-24 PT PT04822235T patent/PT1778837E/pt unknown
- 2004-11-24 CA CA002575300A patent/CA2575300A1/en not_active Abandoned
- 2004-11-24 EP EP04798068A patent/EP1786442B1/de not_active Not-in-force
- 2004-11-24 CA CA002575190A patent/CA2575190A1/en not_active Abandoned
- 2004-11-24 JP JP2007525182A patent/JP2008509172A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
DE602004010314T2 (de) | 2009-03-05 |
EP1778837A1 (de) | 2007-05-02 |
DK1778837T3 (da) | 2008-08-04 |
DE602004013202T2 (de) | 2009-05-28 |
WO2006015622A1 (en) | 2006-02-16 |
ES2304642T3 (es) | 2008-10-16 |
ES2295949T3 (es) | 2008-04-16 |
US20090098105A1 (en) | 2009-04-16 |
ATE392471T1 (de) | 2008-05-15 |
CA2575190A1 (en) | 2006-02-16 |
WO2006015621A1 (en) | 2006-02-16 |
US20070298029A1 (en) | 2007-12-27 |
DK1786442T3 (da) | 2008-03-17 |
EP1786442B1 (de) | 2007-11-21 |
CA2575300A1 (en) | 2006-02-16 |
JP2008509171A (ja) | 2008-03-27 |
EP1786442A1 (de) | 2007-05-23 |
JP2008509172A (ja) | 2008-03-27 |
DE602004013202D1 (de) | 2008-05-29 |
EP1778837B1 (de) | 2008-04-16 |
PT1778837E (pt) | 2008-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20064726L (no) | Imidazolforbindelser for behandling av neurodegenerative forstyrrelser | |
CY1118902T1 (el) | Ρυθμιση της δραστικοτητας των προνευροτροφινων | |
TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
MX2009003468A (es) | Anticuerpo humanizado contra beta amiloide. | |
BR0315158A (pt) | Compostos de pirazol para o tratamento de distúrbios neurodegenarativos | |
CY1109104T1 (el) | 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου | |
DE602004010314D1 (de) | Behandlung von neurodegenerativen erkrankungen durch verwendung von degs-inhibitoren | |
BRPI0413245A (pt) | compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos | |
BRPI0509477A (pt) | compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos | |
ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
MXPA05012196A (es) | Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos. | |
ATE371724T1 (de) | Behandlung neurodegenerativer krankheiten | |
ATE437855T1 (de) | (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit | |
EA200700707A1 (ru) | Производные 2-ациламинотиазола | |
EA201070367A1 (ru) | Производное 6-пиримидинилпиримид-4-она | |
DK1778623T3 (da) | Derivater af 1-phenylalkancarboxylsyrer til behandling af neurodegenerative sygdomme | |
ATE524171T1 (de) | Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit | |
ATE402150T1 (de) | Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen | |
WO2005097114A3 (en) | Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders | |
NO20081845L (no) | Imidazolforbindelser for behandling av neurologiske lidelser | |
EA201070496A1 (ru) | УГЛЕРОД-СВЯЗАННЫЕ МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ | |
EA200501865A1 (ru) | Аналоги тиовольфраматов и их применение | |
EA201070497A1 (ru) | Промежуточные продукты мгс | |
TW200510351A (en) | Oxazole compounds for the treatment of neurodegenerative disorders | |
BRPI0509881A (pt) | combinação terapêutica para tratamento da doença de alzheimer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |